Epratuzumab Phase IIB Data Demonstrated Sensitivity of BICLA, a Novel BILAG-Based Composite Endpoint
ACR Presentation by Lupus LA founder Daniel Wallace, MD
Tuesday, November 8, 2011
S.L.E. Lupus Foundation Board Member and Lupus LA founder Daniel Wallace, MD presented research at ACR demonstrating the effectiveness of a new sensitive composite measure of disease activity in lupus used successfully in two clinical trials.
On the go?
Text INFO to 50555 and opt-in to receive breaking news about lupus on your mobile phone.
Message and Data Rates May Apply. Text STOP to 50555 to STOP. Text HELP to 50555 for HELP. Full Terms